Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging

Oncology Letters

Volumn 8, Issue 3, 2014, Pages 1323-1327

  Gorodkiewicz, Ewa ^a   Guszcz, Tomasz ^b   Roszkowska Jakimiec, Wieslawa ^c   Kozłowski, Robert ^b  

^a UNIVERSITY OF BIALYSTOK   (Poland)

^b III Department of Internal Diseases and Gastroenterology   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bladder cancer; Cathepsin D; Surface plasmone resonance imaging biosensor; Transitional cell carcinoma

Indexed keywords

EID: 84904266092     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2250     Document Type: Article

References (27)

1. Faust PL, Kornfeld S and Chirgwin JM: Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci USA 82: 4910-4914, 1985.
2. Barrett AJ: Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J 117: 601-607, 1970.
3. Têtu B, Brisson J, Côté C, et al: Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 55: 429-435, 1993.
4. Veneroni S, Daidone MG, Di Fronzo C, et al: Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Res Treat 26: 7-13, 1993.
5. Métayé T, Millet C, Kraims JL, et al: Estrogen receptors and cathepsin D in human thyroid tissue. Cancer 72: 1991-1996, 1993.
6. Warwas M and Taurowska E: Cathepsin D in diagnosis of neoplastic diseases. Postepy Hig Med Dosw 47: 277-288, 1993 (In Polish).
7. Ferlay J, Shin HR, Bray F, et al: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer. GLOBOCAN, Lyon, France, 2008. http://globocan.iarc.fr. Accessed 4 July, 2010.
8. Burger M, Catto JW, Dalbagni G, et al: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63: 234-241, 2013.
9. Fernández-González A, Rychłowska J, Badía R and Salzer R: SPR imaging as a tool for detecting mucin-anti-mucin interaction. Outline of the development of a sensor for near-patient testing for mucin. Microchim Acta 158: 219-225, 2007.
10. Lee HJ, Nedelkov D and Corn RM: Surface plasmon resonance imaging measurements of antibody arrays for the multiplexed detection of low molecular weight protein biomarkers. Anal Chem 78: 6504-6510, 2006.
11. Gorodkiewicz E, Regulska E and Roszkowska-Jakimiec W: Determination of the active form concentration of cathepsins D and B by SPRI biosensors. J Lab Diagn 46: 107-109, 2010.
12. Gorodkiewicz E and Regulska E: SPR imaging biosensor for aspartyl cathepsins: sensor development and application for biological material. Protein Pept Lett 17: 1148-1154, 2010.
13. Gorodkiewicz E, Regulska E and Wojtulewski K: Development of an SPR imaging biosensor for determination of cathepsin G in saliva and white blood cells. Mikrochim Acta 173: 407-413, 2011.
14. Gorodkiewicz E, Ostrowska H and Sankiewicz A: SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma. Microchim Acta 175: 177-184, 2011.
15. Gorodkiewicz E, Charkiewicz R, Rakowska A, et al: SPR imaging biosensor for podoplanin: sensor development and application to biological materials. Microchim Acta 176: 337-343, 2012.
16. Gorodkiewicz E: Surface Plasmon Resonance Imaging sensor for cathepsin determination based on immobilized cystatin. Protein Pept Lett 16: 1379-1385, 2009.
17. Tokyol C, Köken T, Demirbas M, et al: Expression of cathepsin D in bladder carcinoma: correlation with pathological features and serum cystatin C levels. Tumori 92: 230-235, 2006.
18. Salman T, el-Ahmady O, el-Shafee M, et al: Cathepsin-D and TNF-alpha in bladder cancer. Dis Markers 12: 253-259, 1996.
19. Kotaska K, Dusek P, Prusa R, et al: Urine and serum cathepsin B concentration in the transitional cell carcinoma of the bladder. J Clin Lab Anal 26: 61-65, 2012.
20. Szajda SD, Darewicz B, Kudelski J, et al: Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer. Pol Merkur Lekarski 18(108): 651-653, 2005.
21. Herr HW: Transuretheral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19: 89-93, 2001.
22. European Association of Urology: Non-muscle-invasive (Ta, T1 and CIS) bladder cancer. http://www.uroweb.org/guidelines/online-guidelines/. Accessed March 13, 2012.
23. American Urological Association: Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1 and Tis): Update (2007). http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm. Accessed November 15, 2007.
24. Elissa S, Swellam M, Sadek M, et al: Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of the bladder tumors. J Urol 168: 465-469, 2002.
25. Menéndez V, Fernández-Suárez A, Galán JA, et al: Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology 65: 284-289, 2005.
26. Lotan Y, Shariat SF, Schmitz-Dräger BJ, et al: Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 28: 441-448, 2010.
27. Catto JWF. Old and new urinary markers: Which one is the PSA for bladder cancer? Eur Urol Suppl 7: 422-425, 2008.